Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Valproate bismuth** is a discrete bismuth(III) salt of valproic acid, consisting of one bismuth cation coordinated with three valproate anions. It is also called **bismuth dipropylacetate** and is the medicinal ingredient in the Canadian non-prescription rectal suppository **Neo-Laryngobis**. Neo-Laryngobis contains 135 mg bismuth dipropylacetate per suppository and is marketed for symptomatic relief associated with pharyngitis, laryngitis, tonsillitis, sore throat, and loss of voice. Its product-specific pharmacological target and mechanism in throat disorders are not established in the identified sources; the well-known central nervous system actions of valproic acid should not be assumed to describe this bismuth-valproate salt or its local throat indication. ([pubchem.ncbi.nlm.nih.gov](https://pubchem.ncbi.nlm.nih.gov/compound/Valproate-bismuth))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on valproate bismuth.